Dicranopteris linearis: a potential medicinal plant with anticancer properties / Dicranopteris linearis: una planta medicinal potencial con propiedades anticancerígenas

Several investigations have demonstrated Dicranopteris linearis (Burm.f.) Underw. (Gleicheniaceae) plant extracts possess numerous health-promoting properties. This review is aimed to summarize and highlight the potential possess by D. linearisto be developed into future pharmacological entity especially as anticancer agent. This study used several electronic search engines to compile and integrate a number of scientific publications related with D. linearis. Scientifically, D. linearishas been reported to have antinociceptive, anti-inflammatory, antipyretic, chemopreventive and antioxidant properties which can be linked to its potential to treat various kinds of ailments including inflammatory-related diseases and cancer. A number of scientific evidences related with anticancer studies suggested the ability of D. linearis-based phytochemicals to act as potent anticancer lead compounds. In conclusion, D. linearis has the potential to be developed into potent anticancer agent as depicted by a number of isolated phytochemicals which can work synergistically to contribute to its anticancer properties.

Varias investigaciones han demostrado que los extractos de la planta Dicranopteris linearis (Burm.f.) Underw. (Gleicheniaceae) poseen numerosas propiedades promotoras de la salud. El objetivo de esta revisión es resumir y resaltar el potencial que posee D. linearispara convertirse en una entidad farmacológica futura, especialmente como agente anticancerígeno. Este estudio utilizó varios motores de búsqueda electrónicos para compilar e integrar una serie de publicaciones científicas relacionadas con D. linearis. Científicamente, se ha informado que D. linearis tiene propiedades antinociceptivas, antiinflamatorias, antipiréticas, quimiopreventivas y antioxidantes que pueden estar vinculadas a su potencial para tratar varios tipos de dolencias, incluidas las enfermedades asociadas a inflamación y el cáncer. Una serie de evidencias científicas relacionadas con los estudios anticancerosos sugirieron la capacidad de los fitoquímicos basados en D. linearis para actuar como potentes compuestos anticancerígenos. En conclusión, D. linearis tiene el potencial de convertirse en una fuente de potentes agentes anticancerígeno, como se describe en una serie de fitoquímicos aislados que pueden actuar de forma sinérgica para contribuir a sus propiedades anticancerígenas.

Safety evaluation of orally-administered methanol extract of Muntingia calabura Linn. leaves: A sub-chronic toxicity study in Sprague Dawley rats.

Muntingia calabura (M. calabura), locally known as "kerukup siam" or "buah ceri" belongs to the family Muntingiaceae and has been scientifically demonstrated to exert various pharmacological activities. The objectives of the current study are to evaluate the antioxidant activities and to determine the subchronic toxicity of 90 days orally-administered methanol extract of M. calabura (MEMC) in male Sprague Dawley rats. The rats were randomly divided into four groups (n=6). Vehicle control received 8% tween 80 and treatment group received 50, 250 and 500 mg/kg of MEMC orally administered daily for 90 days. Blood collection was carried out to obtain the hematological and biochemical profile of the rats. The organs harvested were subjected to histopathological analysis. For the antioxidant test, the extract was subjected to antioxidant study using the 2, 2-diphenyl-1-picrylhydrazyl (DPPH)- and superoxide anion-radical scavenging activity, total phenolic content (TPC) and phytochemical screening. Results obtained show that no adverse effects were observed during the experimental period. Hematological and biochemical analysis also showed no significant changes in this toxicity study. Besides, antioxidant analyses revealed that MEMC has higher DPPH- and SOD-radical scavenges activity as well as higher TPC value. In conclusion, M. calabura is safe for consumption and possesses beneficial antioxidant effect.

Semipurified Ethyl Acetate Partition of Methanolic Extract of Melastoma malabathricum Leaves Exerts Gastroprotective Activity Partly via Its Antioxidant-Antisecretory-Anti-Inflammatory Action and Synergistic Action of Several Flavonoid-Based Compounds.

Recent study has demonstrated the gastroprotective activity of crude methanolic extract of M. malabathricum leaves. The present study evaluated the gastroprotective potential of semipurified extracts (partitions): petroleum ether, ethyl acetate (EAMM), and aqueous obtained from the methanolic extract followed by the elucidation of the gastroprotective mechanisms of the most effective partition. Using the ethanol-induced gastric ulcer assay, all partitions exerted significant gastroprotection, with EAMM being the most effective partition. EAMM significantly (i) reduced the volume and acidity (free and total) while increasing the pH of gastric juice and enhanced the gastric wall mucus secretion when assessed using the pylorus ligation assay, (ii) increased the enzymatic and nonenzymatic antioxidant activity of the stomach tissue, (iii) lost its gastroprotective activity following pretreatment with N-omega-nitro-L-arginine methyl ester (L-NAME; NO blocker) or carbenoxolone (CBXN; NP-SH blocker), (iv) exerted antioxidant activity against various in vitro oxidation assays, and (v) showed moderate in vitro anti-inflammatory activity via the LOX-modulated pathway. In conclusion, EAMM exerts a remarkable NO/NP-SH-dependent gastroprotective effect that is attributed to its antisecretory and antioxidant activities, ability to stimulate the gastric mucus production and endogenous antioxidant system, and synergistic action of several gastroprotective-induced flavonoids.

The role and future potential of fluorinated biomarkers in positron emission tomography.

IMPORTANCE OF THE FIELD: Positron emission tomography (PET) is rapidly emerging as the functional imaging method of choice for in vivo imaging applications in a number of key areas of drug discovery and clinical pathology, but especially in oncology. One key limitation of PET is the requirement for rapid synthesis and purification of biomarker/drug molecules regiospecifically labelled with short-lived positron-emitting isotopes. AREAS COVERED IN THIS REVIEW: In this review, we focus on the role of (18)F-labelled molecules in PET, presenting a perspective on the challenges associated with the synthesis and future clinical utility of a range of labelled small molecules and macromolecular structures. Further preclinical method development for the regiospecific synthesis of fluorinated biomarkers under mild conditions is required before a wide range of (18)F-labelled molecules take their place alongside clinically established oncology biomarkers such as (18)FDG and (18)FLT. WHAT THE READER WILL GAIN: In this review, we offer insights into current and future chemical methods for the efficient synthesis of fluorinated PET biomarkers, featuring modern technologies such as microwave-promoted chemistries and microfluidic reactors, both of which possess the capability to routinely and rapidly produce the small quantities of PET-labelled molecules under the mild and efficient conditions that are required for PET tracer synthesis. TAKE HOME MESSAGE: (18)F PET is a flourishing field with many applications in drug discovery and development, through radiolabelling of drug molecules or use of fluorinated disease biomarkers.